Henrike Reder
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Henrike Reder has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Steffen Wagner
Department of Otorhinolaryngology, Head and Neck Surgery, Justus-Liebig-University Giessen, 35392 Giessen, Germany
3 shared publications Claus Wittekindt
Department of Otorhinolaryngology, Head and Neck Surgery, Justus-Liebig University Giessen, Giessen, Germany
2 shared publications- Claus Wittekindt
Klinikum Dortmund gGmbH
2 shared publications Elena-Sophie Prigge
Department of Applied Tumor Biology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany
2 shared publications- Gregor Wolf
Department of Otorhinolaryngology, Head and Neck Surgery, University of Giessen, Giessen, Germany
2 shared publications - Jens Peter Klussmann
Department of Otorhinolaryngology, Head and Neck Surgery, Medical Faculty, University of Cologne, 50931 Cologne, Germany
2 shared publications
Latest Publications
- Open Access
- 10 June 2021
- Published by Springer Nature in British Journal of Cancer
- Vol. 125 (2) , 307
Correction: Evaluation of p16INK4a expression as a single marker to select patients with HPV-driven oropharyngeal cancers for treatment de-escalation
- 10 June 2021
- Published by Springer Nature in British Journal of Cancer
- Vol. 125 (2) , 307
Open AccessCorrection: Evaluation of p16INK4a expression as a single marker to select patients with HPV-driven oropharyngeal cancers for treatment de-escalation
- 1 November 2020
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 22 (11) , 1333-1343
Plasma Cell-Free Human Papillomavirus Oncogene E6 and E7 DNA Predicts Outcome in Oropharyngeal Squamous Cell Carcinoma
- 1 November 2020
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 22 (11) , 1333-1343
Plasma Cell-Free Human Papillomavirus Oncogene E6 and E7 DNA Predicts Outcome in Oropharyngeal Squamous Cell Carcinoma
- Open Access
- 6 July 2020
- Published by Springer Nature in British Journal of Cancer
- Vol. 123 (7) , 1114-1122
Evaluation of p16INK4a expression as a single marker to select patients with HPV-driven oropharyngeal cancers for treatment de-escalation
Background: A remarkably better prognosis is associated with oropharyngeal squamous cell carcinomas (OPSCC) driven by human papillomaviruses (HPV) compared with HPV-negative OPSCC. Consequently, de-escalation of standard treatment has been suggested. Due to modest specificity rates, debates are ongoing, whether p16INK4a, a surrogate marker for HPV-driven OPSCC, is sufficient to correctly identify those tumours and avoid substantial HPV misattribution and thus undertreatment of patients by de-escalation. Robust data estimating the proportion of potentially undertreated patients are missing. Methods: We assessed a large-scale cohort of consecutively included OPSCC diagnosed between 2000 and 2017 for HPV–DNA, HPV genotypes, p16INK4a expression and multiple tumour- and patient-related risk factors, and investigated their impact on patients’ survival in comprehensive uni- and multivariate analyses. Results: Aetiological relevance of HPV (p16INK4a- and high-risk HPV–DNA-positivity) was detected in 27.1% (n = 192) of OPSCC, with HPV16 being the most abundant HPV type (94.6%). In 5.5% patients (n = 39), p16INK4a overexpression but no HPV–DNA was detected. Principal component and survival analyses revealed that 60.6% of these p16INK4a-positive OPSCC lacking HPV–DNA did not resemble HPV16-driven but HPV-negative OPSCC regarding risk-factor profile and overall survival. Notably, this group represented 10.6% of all p16INK4a-overexpressing OPSCC. Conclusions: p16INK4a as a single marker appears insufficient to indicate OPSCC patients suitable for treatment de-escalation.
- 6 July 2020
- Published by Springer Nature in British Journal of Cancer
- Vol. 123 (7) , 1114-1122
Open AccessEvaluation of p16INK4a expression as a single marker to select patients with HPV-driven oropharyngeal cancers for treatment de-escalation
Background: A remarkably better prognosis is associated with oropharyngeal squamous cell carcinomas (OPSCC) driven by human papillomaviruses (HPV) compared with HPV-negative OPSCC. Consequently, de-escalation of standard treatment has been suggested. Due to modest specificity rates, debates are ongoing, whether p16INK4a, a surrogate marker for HPV-driven OPSCC, is sufficient to correctly identify those tumours and avoid substantial HPV misattribution and thus undertreatment of patients by de-escalation. Robust data estimating the proportion of potentially undertreated patients are missing. Methods: We assessed a large-scale cohort of consecutively included OPSCC diagnosed between 2000 and 2017 for HPV–DNA, HPV genotypes, p16INK4a expression and multiple tumour- and patient-related risk factors, and investigated their impact on patients’ survival in comprehensive uni- and multivariate analyses. Results: Aetiological relevance of HPV (p16INK4a- and high-risk HPV–DNA-positivity) was detected in 27.1% (n = 192) of OPSCC, with HPV16 being the most abundant HPV type (94.6%). In 5.5% patients (n = 39), p16INK4a overexpression but no HPV–DNA was detected. Principal component and survival analyses revealed that 60.6% of these p16INK4a-positive OPSCC lacking HPV–DNA did not resemble HPV16-driven but HPV-negative OPSCC regarding risk-factor profile and overall survival. Notably, this group represented 10.6% of all p16INK4a-overexpressing OPSCC. Conclusions: p16INK4a as a single marker appears insufficient to indicate OPSCC patients suitable for treatment de-escalation.
- 1 June 2019
- Published by Elsevier in Oral Oncology
- Vol. 93, 59-65
Genetic alterations in human papillomavirus-associated oropharyngeal squamous cell carcinoma of patients with treatment failure
- 1 June 2019
- Published by Elsevier in Oral Oncology
- Vol. 93, 59-65
Genetic alterations in human papillomavirus-associated oropharyngeal squamous cell carcinoma of patients with treatment failure